Response by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism"

Circulation. 2020 Oct 27;142(17):e264. doi: 10.1161/CIRCULATIONAHA.120.050174. Epub 2020 Oct 26.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cholesterol, LDL
  • Humans
  • Proprotein Convertase 9*
  • Subtilisins
  • Venous Thromboembolism* / diagnosis
  • Venous Thromboembolism* / epidemiology
  • Venous Thromboembolism* / prevention & control

Substances

  • Cholesterol, LDL
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • Subtilisins